Observational studyBMC musculoskeletal disorders2026
MRI severity of common extensor origin damage associated with prior glucocorticoid injection in chronic lateral epicondylitis: a retrospective multicenter analysis.
Observational study in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLateral epicondylitis (LE) is a degenerative tendinopathy of the common extensor origin (CEO). Although local glucocorticoid injections are widely used for symptom relief, concerns exist regarding their potential adverse effects on tendon structure. This study aimed to investigate the association between prior glucocorticoid injection and magnetic resonance imaging (MRI)-based structural CEO damage in patients with chronic LE.
methodsIn this retrospective, multicenter cross-sectional study, 147 patients with clinically diagnosed LE (symptom duration ≥ 6 months) who underwent elbow MRI between 2015 and 2023 were included. The primary exposure was prior local glucocorticoid injection at the CEO (yes/no and number of injections). Structural tendon damage was assessed using the Walz classification and quantitative lesion size diameters measured in coronal, axial, and sagittal MRI planes. Associations were analyzed using proportional odds ordinal logistic regression and generalized linear models, adjusted for age, sex, occupational workload, study center, and symptom duration.
resultsSixty-three patients (42.9%) had received at least one prior glucocorticoid injection. Prior injection was independently associated with more severe MRI-based tendon damage. Patients with prior injection had higher odds of being classified in a higher Walz grade compared with non-injected patients (adjusted odds ratio (OR) 2.78, 95% confidence interval (CI) 1.30-5.97; p = .008). Longer symptom duration was also associated with higher Walz grades (adjusted OR 1.02 per month, 95% CI 1.00-1.04; p = .031). Among injected patients, the number of injections was not significantly associated with Walz grade. Prior injection was further associated with larger lesion size diameters: +2.07 mm in the coronal plane (95% CI 0.80-3.34; p = .001), + 1.49 mm in the axial plane (95% CI 0.21 - 2.76; p = .022), and a 94% larger sagittal diameter (ratio 1.94, 95% CI 1.15-3.29; p = .013).
conclusionsPrior local glucocorticoid injection at the CEO was associated with more severe MRI-detected structural tendon abnormalities in patients with chronic LE. However, the retrospective cross-sectional design and potential for confounding by indication preclude causal attribution of these structural differences to glucocorticoid exposure. These findings provide imaging-based evidence supporting a cautious and selective approach to glucocorticoid injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.